Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 5/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17821679 | 0.94 | MTNR1B (0.46) | MTNR1BMTNR1AMEN1KMT2AGRIN2C | |
| SCHEMBL20909399 | 0.91 | MTNR1B (0.47) | MTNR1BMTNR1AMEN1KMT2AGRIN2C | |
| SCHEMBL17822008 | 0.89 | MTNR1B (0.48) | MTNR1BMTNR1AMEN1KMT2AGRIN2C | |
| SCHEMBL17864820 | 0.86 | MTNR1B (0.45) | MTNR1BMTNR1AMEN1KMT2AGRIN2C | |
| SCHEMBL17821818 | 0.81 | MTNR1B (0.45) | MTNR1BMTNR1AMEN1KMT2ALMNA | |
| SCHEMBL20705812 | 0.80 | MTNR1B (0.45) | MTNR1BMTNR1AMEN1KMT2AGRIN2C | |
| SCHEMBL17864800 | 0.80 | MTNR1B (0.43) | MTNR1BMTNR1AMEN1KMT2APDE4D | |
| SCHEMBL17864742 | 0.78 | MTNR1B (0.43) | MTNR1BMTNR1AMEN1KMT2APDE4D | |
| SCHEMBL17864731 | 0.76 | KCNN2 (0.44) | MTNR1BKMT2AGRIN2CCYP2D6LMNA | |
| SCHEMBL17821736 | 0.75 | MTNR1B (0.55) | MTNR1BMTNR1AMEN1KMT2AGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | MTNR1B 3891/4885MTNR1A 4263/4885MEN1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.